Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
597.59M | 493.65M | 451.17M | 438.75M | 398.56M | 380.24M | Gross Profit |
347.69M | 326.54M | 297.12M | 282.01M | 252.40M | 239.84M | EBIT |
161.09M | 107.08M | 103.75M | 101.92M | 98.44M | 90.79M | EBITDA |
162.70M | 128.33M | 122.93M | 121.35M | 110.84M | 100.26M | Net Income Common Stockholders |
118.42M | 111.36M | 91.90M | 89.50M | 82.39M | 72.55M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
47.75M | 72.14M | 47.75M | 84.10M | 73.41M | 93.14M | Total Assets |
776.03M | 853.08M | 776.03M | 725.67M | 641.76M | 564.15M | Total Debt |
8.23M | 1.99M | 23.90M | 32.69M | 16.44M | 13.89M | Net Debt |
-26.41M | -62.23M | -10.75M | -33.73M | -53.81M | -77.32M | Total Liabilities |
112.44M | 126.46M | 112.68M | 123.39M | 103.70M | 91.27M | Stockholders Equity |
662.36M | 725.87M | 662.36M | 601.08M | 536.53M | 471.39M |
Cash Flow | Free Cash Flow | ||||
44.47M | 75.95M | -1.22M | 25.84M | 20.23M | 52.77M | Operating Cash Flow |
105.82M | 115.47M | 100.97M | 106.79M | 79.64M | 78.49M | Investing Cash Flow |
-55.22M | -34.18M | -97.36M | -92.17M | -83.48M | -25.78M | Financing Cash Flow |
-24.17M | -51.71M | -35.38M | -18.46M | -17.12M | -14.35M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
80 Outperform | €1.34B | 11.99 | 16.04% | 2.97% | 9.42% | 20.43% | |
54 Neutral | $5.31B | 3.29 | -45.39% | 2.79% | 16.77% | -0.07% | |
€2.37B | 232.50 | 0.69% | 1.33% | ― | ― | ||
€6.32B | 26.77 | 3.37% | ― | ― | ― | ||
€263.54M | 23.59 | 5.11% | 1.24% | ― | ― | ||
€2.80B | 20.25 | 25.24% | 1.62% | ― | ― | ||
$1.72B | 78.75 | 10.15% | 0.73% | ― | ― |
Faes Farma, S.A. has completed the acquisition of Laboratorios Edol, a leading Portuguese ophthalmology company, as part of its strategic plan to enhance its presence in Portugal and expand its international growth. This acquisition, valued at 75 million euros, is expected to create synergies with Faes Farma’s current R&D efforts and support business growth in new therapeutic areas.
Faes Farma, S.A. has announced the convening of its General Shareholders’ Meeting, scheduled for June 24 or 25, 2025, to discuss and approve key financial and management reports for the 2024 fiscal year. The meeting will also address the appointment of a new independent director and include an advisory vote on the directors’ remuneration report, reflecting the company’s ongoing governance and strategic planning efforts.
Faes Farma has announced a webcast for analysts and investors to present its first quarter 2025 results. The webcast, featuring key company executives, will include a Q&A session and aims to provide insights into the company’s financial performance and strategic direction.
Faes Farma held its Capital Markets Day to outline its strategic plan for 2025-2030, emphasizing transformation and future growth. The plan focuses on four strategic axes, highlighting the company’s ambition to strengthen its organizational culture and expand its international business operations.
Faes Farma, a company operating in the pharmaceutical industry, has announced its Capital Markets Day event to unveil the Group’s new Strategic Plan. This event will outline the company’s objectives and growth strategies for the upcoming years, potentially impacting its market positioning and providing insights for stakeholders.
Faes Farma, S.A. has announced the acquisition of Laboratorios Edol, a leading Portuguese ophthalmology laboratory, for 75 million euros. This strategic move is expected to double Faes Farma’s sales and EBITDA in Portugal, enhance its international market presence, and create synergies with its current R&D team, particularly in the growing field of ophthalmology.